Oxlumo(lumasiran)
Oxlumo (lumasiran) is an oligonucleotide pharmaceutical. Lumasiran was first approved as Oxlumo on 2020-11-19. It has been approved in Europe to treat primary hyperoxaluria.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Oxlumo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lumasiran sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OXLUMO | Alnylam Pharmaceuticals | N-214103 RX | 2020-11-23 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| oxlumo | New Drug Application | 2025-04-07 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LUMASIRAN SODIUM, OXLUMO, ALNYLAM PHARMS INC | |||
| 2029-10-06 | ODE-415 | ||
| 2027-11-23 | ODE-339 | ||
| 2025-11-23 | NCE | ||
| 2025-10-06 | I-901 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Lumasiran Sodium, Oxlumo, Alnylam Pharms Inc | |||
| 11261447 | 2038-11-20 | DS, DP | U-2995 |
| 10478500 | 2035-10-09 | DS, DP | U-2995 |
| 11446380 | 2035-10-09 | DS, DP | |
| 10612024 | 2035-08-14 | DS, DP | U-2995 |
| 10612027 | 2035-08-14 | DS, DP | U-2995 |
| 11401517 | 2035-08-14 | DS, DP | U-2995 |
| 9828606 | 2034-12-26 | DS, DP | |
| 10435692 | 2034-12-26 | U-2995 | |
| 10465195 | 2034-12-26 | DS, DP | U-2995 |
| 10487330 | 2034-12-26 | DS, DP | U-2995 |
| 11060093 | 2034-12-26 | DS, DP | U-2995 |
| 8106022 | 2029-12-12 | DS, DP | U-2995 |
| 8828956 | 2028-12-04 | DS, DP | U-2995 |
| 10131907 | 2028-08-24 | DS, DP | U-2995 |
HCPCS
Code | Description |
|---|---|
| J0224 | Injection, lumasiran, 0.5 mg |
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Primary hyperoxaluria | D006960 | — | E72.53 | 1 | 2 | 3 | — | 2 | 7 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rnai therapeutics | D000067492 | — | — | — | 1 | — | — | — | 1 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
| Nephrolithiasis | D053040 | — | N20.0 | — | 1 | — | — | — | 1 |
| Kidney calculi | D007669 | EFO_0004253 | N20 | — | 1 | — | — | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | — | — | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | — | 1 |
| Heart disease risk factors | D000082742 | — | — | — | 1 | — | — | — | 1 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | 1 | — | — | — | 1 |
| Hyperoxaluria | D006959 | — | E72.53 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lumasiran |
| INN | lumasiran |
| Description | Lumasiran, sold under the brand name Oxlumo, is a medication for the treatment of primary hyperoxaluria type 1 (PH1).
|
| Classification | Oligonucleotide |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1834610-13-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297779 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15935 |
| UNII ID | RZT8C352O1 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Oxlumo – Alnylam Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 684 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
268 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use